ACADIA Pharmaceuticals In... (ACAD)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted induce...

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Morgan Stanley upgraded Acadian Asset Management to Equal Weight from Underweight with a price target of $26, up from $25. The company's skew to overseas assets will insulate its possible downside to ...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: M...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability ...

Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago...

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see s...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March ...